Marija Antunovic, Janja Raonic



Introduction: Survivin functions as an apoptosis inhibitor and a regulator of cell division. This study aimed to determine the correlation between survivin expression and clinicopathologic parameters of oral squamous cell carcinoma (OSCC) and determine its potential role in the progression/prognosis of this type of tumor.

Materials and methods: Immunohistochemical analysis of survivin expression was performed on 45 surgically obtained paraffin-embedded tissue samples of OSCCs. Data on patients’ gender, age, tumor grade, site and stage, disease recurrence, metastasis occurrence, and disease-free interval (DFI) were correlated to survivin expression.

Results: Survivin immunoreactivity was observed in 77.8% of samples. No significant correlation between survivin expression and age (p = 0.087), gender (p = 0.334), tumor site (p = 0.175), presence of lymph node metastases (p = 0.201), or disease recurrence (p = 0.451) was found. Survivin expression was observed in well and moderately differentiated tumors and in all clinical stages (p = 0.139). Patients with low survivin expression had better survival rates than the group with medium and high survivin expression, i.e., there was a tendency of a shorter DFI in patients with higher expression of survivin (p = 0.065).

Conclusion: There is a tendency for a shorter disease-free period in patients with higher survivin expression. These data suggest that survivin expression in OSCC may act as an additional prognostic parameter that indicates an increased proliferative tumor potential. To further validate survivin as a prognostic marker in OSCC, a study with a larger sample size along with clinical follow-up data is needed.



survivin, oral squamous cell carcinoma, prognosis





Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. 2002. CA Cancer J Clin. 2005; 55(2):74-108. doi:10.3322/canjclin.55.2.74.

Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998; 396(6711):580-4. doi: 10.1038/25141.

Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res. 2004; 64(20):7183-90.doi: 10.1158/0008-5472.CAN-04-1918.

Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, et al. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene. 2000; 19(5):617-23. doi: 10.1038/sj.onc.1203358.

Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology. 2000, 31(5):1080-5. doi: 10.1053/he.2000.6496.

Konno R, Yamakawa H, Utsunomiya H, Ito KM, Sato S, Yajima A. Expression of survivin and Bcl-2 in the normal human endometrium. Mol Hum Reprod. 2000; 6(6):529-34. doi: 10.1093/molehr/6.6.529.

Gianani R, Jarboe E, Orlicky D, Frost M, Bobak J, Lehner R, et al. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol. 2001; 32(1):119-25.doi: 10.1053/hupa.2001.21897.

Zhou LQ, Hu Y, Xiao HJ. The prognostic significance of survivin expression in patients with HNSCC: a systematic review and meta-analysis. BMC Cancer. 2021;21(1):424. doi: 10.1186/s12885-021-08170-3.

Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer. 2001; 91(11):2026-32. doi: 10.1002/10970142(20010601)91:11<2026::aid-cncr1228>;2-e.

Lodi G, Franchini R, Bez C, Sardella A, Moneghini L, Pellegrini C et al. Detection of survivin mRNA in healthy oral mucosa, oral leucoplakia and oral cancer. Oral Dis. 2010; 16(1):61-7.doi: 10.1111/j.1601-0825.2009.01614.x.

Engels K, Knauer SK, Metzler D, Simf C, Struschka O, Bier C, et al. Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J Pathol. 2007; 211(5):532-40. 40.doi: 10.1002/path.2134.

Saito T, Arifin MT, Hama S, Kajiwara Y, Sugiyama K, Yamasaki F, et al. Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker. J Neurooncol. 2007; 82(2):193-8.doi:10.1007/s11060-006-9267-1.

Lo Muzio L, Pannone G, Staibano S, Mignogna MD, Rubini C, Mariggio MA et al. Survivin expression in oral squamous cell carcinoma. Br J Cancer. 2003; 89(12):2244-8.doi: 10.1038/sj.bjc.6601402.

Kumamoto H, Ooya K. Expression of survivin and X chromosome-linked inhibitor of apoptosis protein in ameloblastomas. Virchows Arch. 2004;444(2):164-70.doi: 10.1007/s00428-003-0941-9.

de Oliveira MG, Lauxen Ida S, Chaves AC, Rados PV, Sant’ana Filho M. Odontogenic epithelium: Immunolabeling of Ki-67, EGFR and survivin in pericoronal follicles, dentigerous cysts and keratocystic odontogenic tumors. Head Neck Pathol. 2011; 5(1):1-7. doi: 10.1007/s12105-010-0216-0.

Andric M, Dozic B, Popovic B, Stefanovic D, Basta-Jovanovic G, Djogo N, et al. Survivin expression in odontogenic keratocysts and correlation with cytomegalovirus infection. Oral Dis. 2010; 16(2):156-9. doi: 10.1111/j.1601-0825.2009.01612.x.

Fukuda S, Pelus LM. Regulation of the inhibitorofapoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoesis. Blood. 2001; 98(7):2091-100. doi:10.1182/blood.V98.7.2091.

Duffy MJ, O’Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Survivin: a promising tumor biomarker. Cancer Lett. 2007; 249(1):49-60.doi: 10.1016/j.canlet.2006.12.020.

Ko YH, Roh SY, Won HS, Jeon EK, Hong SH, Lee MA et al. Prognostic significance of nuclear survivin expression in resected adenoid cystic carcinoma of the head and neck. Head Neck Oncol. 2010; 2:30. doi: 10.1186/1758-3284-2-30.

Halasova E, Adamkov M, Kavcová E, Matáková T, Musák L, Vyubohová M, et al. Expression of anti-apoptotic protein survivin and tumor suppressor p53 protein in patients with pulmonary carcinoma. Eur J Med Res. 2009; 14(suppl 4):97-100.doi: 10.1186/2047-783x-14-s4-97.

Monzó M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J, et al. A novel antiapoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol. 1999; 17(7): 2100-4. doi: 10.1200/JCO.1999.17.7.2100.

Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, ShimosegawaT. Tumor necrosis factor related apoptosis inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. Pancreas. 2001; 23(3):251-8.doi: 10.1097/00006676-200110000-00005.

Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998; 58(22):5071- 4.

Kappler M, Bache M, Bartel F, Kotzsch M, Panian M, Würl P, et al. Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther. 2004; 11(3):186-93.doi: 10.1038/sj.cgt.7700677.

Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol. 1999; 113(6):1076-81. doi: 10.1046/j.1523-1747.1999.00776.x.

Stenner M, Weinell A, Ponert T, Hardt A, Hahn M, Preuss SF et al. Cytoplasmic expression of survivin is an independent predictor of poor prognosis in patients with salivary gland cancer. Histopathology. 2010; 57(5):699-706.doi: 10.1111/j.1365-2559.2010.03693.x.

Qi G, Tuncel H, Aoki E, Tanaka S, Oka S, Kaneko I et al. Intracellular localization of survivin determines biological behavior in colorectal cancer. Oncol Rep. 2009; 22(3):557-62. doi: 10.3892/or_00000471



  • There are currently no refbacks.

Copyright (c) 2023 Marija Antunovic, Janja Raonic

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Scroll to Top